



HAL
open science

Reduction of Fmr1 mRNA Levels Rescues Pathological Features in Cortical Neurons in a Model of FXTAS

Malgorzata Drozd, Sébastien Delhayé, Thomas Maurin, Sara Castagnola, Mauro Grossi, Frédéric Brau, Marielle Jarjat, Rob Willemsen, Maria Capovilla, Renate Hukema, et al.

► To cite this version:

Malgorzata Drozd, Sébastien Delhayé, Thomas Maurin, Sara Castagnola, Mauro Grossi, et al.. Reduction of Fmr1 mRNA Levels Rescues Pathological Features in Cortical Neurons in a Model of FXTAS. *Molecular Therapy - Nucleic Acids*, 2019, 18, pp.546-553. 10.1016/j.omtn.2019.09.018 . hal-02390850

HAL Id: hal-02390850

<https://hal.science/hal-02390850>

Submitted on 18 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Reduction of *Fmr1* mRNA Levels Rescues Pathological Features in Cortical Neurons in a Model of FXTAS

Malgorzata Drozd,^{1,4} Sébastien Delhaye,^{1,4} Thomas Maurin,^{1,4} Sara Castagnola,¹ Mauro Grossi,¹ Frédéric Brau,¹ Marielle Jarjat,¹ Rob Willemsen,² Maria Capovilla,¹ Renate K. Hukema,² Enzo Lalli,³ and Barbara Bardoni³

¹Université Côte d'Azur, CNRS, Institute of Molecular and Cellular Pharmacology, 06560 Valbonne Sophia Antipolis, France; ²Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands; ³Université Côte d'Azur, INSERM, CNRS, Institute of Molecular and Cellular Pharmacology, 06560 Valbonne Sophia Antipolis, France

Fragile X-associated tremor ataxia syndrome (FXTAS) is a rare disorder associated to the presence of the fragile X premutation, a 55–200 CGG repeat expansion in the 5' UTR of the *FMRI* gene. Two main neurological phenotypes have been described in carriers of the CGG premutation: (1) neurodevelopmental disorders characterized by anxiety, attention deficit hyperactivity disorder (ADHD), social deficits, or autism spectrum disorder (ASD); and (2) after 50 years old, the FXTAS phenotype. This neurodegenerative disorder is characterized by ataxia and a form of parkinsonism. The molecular pathology of this disorder is characterized by the presence of elevated levels of *Fragile X Mental Retardation 1 (FMRI)* mRNA, presence of a repeat-associated non-AUG (RAN) translated peptide, and *FMRI* mRNA-containing nuclear inclusions. Whereas in the past FXTAS was mainly considered as a late-onset disorder, some phenotypes of patients and altered learning and memory behavior of a mouse model of FXTAS suggested that this disorder involves neurodevelopment. To better understand the physiopathological role of the increased levels of *Fmr1* mRNA during neuronal differentiation, we used a small interfering RNA (siRNA) approach to reduce the abundance of this mRNA in cultured cortical neurons from the FXTAS mouse model. Morphological alterations of neurons were rescued by this approach. This cellular phenotype is associated to differentially expressed proteins that we identified by mass spectrometry analysis. Interestingly, phenotype rescue is also associated to the rescue of the abundance of 29 proteins that are involved in various pathways, which represent putative targets for early therapeutic approaches.

INTRODUCTION

The *Fragile X Mental Retardation 1 (FMRI)* gene encodes the fragile X mental retardation protein (FMRP), an RNA binding protein whose functional absence causes fragile X syndrome (FXS), the most common form of intellectual disability (ID) and autism spectrum disorder (ASD). The mutation in the *FMRI* gene causing FXS is the presence of a repeated sequence encompassing >200 CGG repeats in its 5' UTR. Hypermethylation of this sequence determines

gene promoter inactivation, causing the silencing of the *FMRI* gene.¹ Although 6–54 CGG repeats in the 5' UTR of *FMRI* is a polymorphism in normal individuals, a repeat sequence of variable length (55–200 CGG repeats) represents the premutation¹ that can cause fragile X tremor ataxia syndrome (FXTAS) in patients over 50 years of age.^{2,3} This is an adult-onset progressive neurodegenerative disorder leading to a variable combination of ataxia, essential tremor, gait imbalance, parkinsonism, peripheral neuropathy, anxiety, and cognitive decline, occurring predominantly in older men carrying the premutation. It is known that people carrying the premutation have a reduced hippocampal volume that correlates with impaired performance in standardized tests of memory.³ At the cellular level, this disorder is characterized by the presence of eosinophilic, ubiquitin-positive nuclear inclusions, which have been observed throughout the brain, with a high percentage being located in the hippocampus of patients, as well as in the animal model of the disease.^{3,4} Inclusions are negative for tau isoforms, alpha-synuclein, or polyglutamine peptides, reflecting a new class of inclusion disorder.³ At the molecular level, FXTAS is characterized by an elevated (2- to 8-fold) level of *FMRI* mRNA, whereas the level of FMRP is normal or slightly reduced in patients, as well in the CGG-KI mouse model.^{2–4} The *FMRI* mRNA is a component of nuclear inclusions³. The product of repeat-associated non-ATG (RAN) translation of the *FMRI* mRNA was also reported to be involved in the generation of inclusions when overexpressed.^{5,6} Although FXTAS is a late-onset disorder, it is also characterized by a set of developmental hallmarks, such as self-reported memory problems, autism-related traits, attention deficit hyperactivity disorder (ADHD), executive functioning, and psychopathology.⁷ Knockin (KI) mouse models have been generated displaying both neurodegenerative and neurodevelopmental

Received 18 July 2019; accepted 8 September 2019;
<https://doi.org/10.1016/j.omtn.2019.09.018>.

⁴These authors contributed equally to this work.

Correspondence: Barbara Bardoni, Université Côte d'Azur, INSERM, CNRS, Institute of Molecular and Cellular Pharmacology, 06560 Valbonne Sophia Antipolis, France.

E-mail: bardoni@ipmc.cnrs.fr






Figure 1. Role of *Fmr1* mRNA Levels in Dendritic Arborization

(A) RNA was prepared from cultured WT and knockin-CGG (KI-CGG) neurons transduced with the control (C) shRNA or two different shRNAs directed against *Fmr1* mRNA (1a and 1b). The level of *Fmr1* mRNA was measured by qRT-PCR using specific primers. Ten different experiments have been carried out for each transduced lentivirus, and a reduction of *Fmr1* levels was observed by using both shRNAs. Results are presented as mean \pm SEM; one-way ANOVA with Tukey's multiple comparisons test, ** $p < 0.01$. (B) Representative western blot analysis of cell cultures of cortical neurons transduced with C, 1a, or 1b shRNAs. FMRP (70 kDa) and β -tubulin (50 kDa) were revealed with specific antibodies. (C) Image of WT and KI-CGG cortical neurons transduced with lentiviruses expressing C, 1a, or 1b shRNAs. Scale bars: 20 μ m. (D) Sholl analysis of WT and KI cultured mouse cortical neurons transduced with C or 1a or 1b shRNAs. Reduced arborization of KI-CGG neurons is rescued by *Fmr1* knockdown. Two-way ANOVA was used to compare KI-C and 1a treatments: genotype F(2; 1,527) = 227.9, $p < 0.0001$; treatment (34; 1,527) = 34.12, $p < 0.0001$; interaction F(68; 1,527) = 3.067, $p < 0.0001$; two-way ANOVA was used to compare KI-C and 1b treatments: genotype F(2; 1,318) = 293.6, **** $p < 0.0001$; treatment F(34; 1,318) = 36.21, **** $p < 0.0001$; interaction F(68; 1,318) = 3,803, $p < 0.0001$.

phenotypes. It was reported that neuronal abnormalities and behavioral alterations in the animal model are present before the appearance of neuronal inclusions. Indeed, cultured hippocampal neurons obtained from a CGG-KI display shorter dendritic length and reduced dendritic complexity.^{4,8-10} In CGG-KI mice, cortical migration is also affected. Indeed, at embryonic day (E) 17, a 2-fold higher percentage of migrating neurons was detected to be oriented toward the ventricle in wild-type (WT) compared with CGG-KI mice.¹¹ All of these abnormalities were observed in inclusion-free cells, because CGG-KI mice display ubiquitin-positive intranuclear inclusions in neurons and astrocytes of the hippocampus and cerebellar internal cell layer starting at 12 weeks of age.^{4,8,9,11} Here we investigated the impact of normalization of *Fmr1* mRNA levels on the morphology and proteomics of cortical cultured neurons obtained from a FXTAS mouse model (CGG-KI)^{8,9} before the generation of nuclear inclusions. By this analysis we have obtained a deeper insight into the physiopathological role of *Fmr1* mRNA levels in FXTAS and identified putative targetable pathways for early treatments.

RESULTS

Hippocampal neurons were isolated from knockin-CGG (KI-CGG) E15.5 mice harboring the CGG premutated allele. It has been shown that these mice display abnormal cortical neuron migration patterns *in utero*.^{10,11} Furthermore, abnormal dendritic architecture and reduced cellular viability have been observed in hippocampal primary neurons of KI-CGG mice, where increased expression of *Fmr1* is already present even if nuclear inclusions are not detected.¹⁰ Indeed, nuclear inclusions appear first in the hippocampus of these mice at the age of 3 months, whereas the same hallmark appears later in the parietal neocortex.^{8,9} We decided to explore whether cultured cortical neurons obtained from these mice have an abnormal

morphology of dendrites and axons during development before the appearance of nuclear inclusions. We studied the dendritic arborization of wild-type (WT) and KI-CGG cortical neurons by Sholl analysis, as previously described,¹² and observed that KI-CGG neurons have a reduced arborization compared with controls (Figures S1A and S1B). To assess whether *Fmr1* mRNA levels impact the morphology of these cultured neurons, we produced lentiviruses expressing two different shRNAs selectively reducing the expression of *Fmr1* mRNA (sh-1a and sh-1b) and one shRNA control (sh-C),¹³ and we used them to transduce cortical cultured neurons obtained from WT and from KI-CGG mice. The infection was performed at 5 DIV (days *in vitro*), and RNA and proteins were prepared from these cultures at 20 DIV. As expected,^{4,13} *Fmr1* mRNA levels were elevated 2-fold in cultured KI cortical neurons compared with WT. sh-1a reduced *Fmr1* transcript levels by 30%, whereas sh-1b reduced them by 50%, (Figure 1A). FMRP levels are not changed in KI cultured neurons compared with WT,^{10,13} and as previously shown in patients.^{2,3} Similarly, the expression level of FMRP was not affected by *Fmr1* knockdown in KI neurons (Figure 1B), as we already observed by transfecting fibroblasts obtained from FXTAS patients with the same shRNAs.¹³ We then analyzed the arborization of WT and KI cortical neurons transduced with *Fmr1* shRNAs. We confirmed that KI neurons transduced with the lentivirus expressing the control shRNA (KI-C) are less arborized than WT neurons transduced with the same lentivirus (Figures 1C and 1D). However, KI neurons transduced with lentivirus expressing either sh-1a or sh-1b displayed a normal dendritic arborization (Figures 1C and 1D).

In 2 DIV neurons we measured the axon length, and we found that they are significantly shorter in *Fmr1*-KI neurons compared with




Figure 2. *Fmr1* mRNA Levels Are Associated to Axon Growth

(A) Representative pictures of 2 days *in vitro* cultured WT-C, KI-C, KI-1a, and KI-1b primary cortical neurons. Scale bars: 10 μm. (B) Histogram of axon length of WT and KI cultured neurons transfected with C, 1a, or 1b shRNAs. Results show mean axon length ± SEM of 150 randomly selected cells for each condition from three independent cultures. One-way ANOVA with Tukey's multiple comparisons test, * $p < 0.05$.

WT (Figure S2). We confirmed that KI-C neurons have shorter axons than WT-C, but the length of these axons was normalized in KI-1a and KI-1b neurons (Figures 2A and 2B).

We then focused on dendritic spine abnormalities. The absence of FMRP causes a peculiar morphology of dendritic spines that has been described in FXS patients and in the mouse model, where it is particularly evident in young animals.^{14,15} Conversely, the study of dendritic spines in the brain of FXTAS patients was never reported, and in *Fmr1* KI mice it was studied only in hippocampi and in the visual cortex from adult animals, displaying an increased length of spines.^{4,16} Here we studied the morphology of dendritic spines of 20 DIV cultured cortical neurons. KI-C spines are longer, denser, and larger than controls. All of these hallmarks are rescued in KI-1a and KI-1b neurons (Figures 3A–3D), indicating that the elevated level of *Fmr1* mRNA causes a set of morphological alterations in KI-CGG neurons. However, the percentage of the different types of spines (thin, stubby, and mushroom) is not significantly different in the two genotypes (Figures 3E–3G).

To get deeper insight into the molecular pathology of FXTAS cultured neurons, we performed a proteomic analysis of neurons that have been transduced with control shRNA or with the shRNAs targeting the *Fmr1* mRNA. Protein extracts of three replicates for each condition were analyzed by nano-liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS) after tryptic digestion.¹⁷ A total of 487 proteins were identified (Table S1), among which 251 have a ratio >2 (upregulation) or <0.5 (downregulation) for at least one of the three comparisons (WT-C versus KI-C, WT-C versus KI-1a, and WT-C versus KI-1b) with a p value <0.10 . Interestingly, the abundance of 29 differentially expressed proteins is rescued after reduction of *Fmr1* mRNA by using both specific shRNAs (Table 1). Gene Ontology analysis of these proteins reveals a significant enrichment of proteins involved in different biochemical pathways, among which are GTP binding and RNA binding proteins (Figure 4; Table S2).

DISCUSSION

Two main neurological phenotypes have been described in carriers of the CGG premutation: those exhibiting neurodevelopmental disorders characterized by anxiety, ADHD, social deficits, or ASD, and after 50 years old, FXTAS, a neurodegenerative disorder.³ For some time, nuclear inclusions have been considered as the cause of neurodegeneration, whereas more recent studies suggest that nuclear inclusions may represent a mechanism used by neurons to protect themselves from toxic events.^{4,18–20} So far, two other main physiopathological elements are known to underpin the FXTAS phenotype: the elevated abundance of *FMR1* mRNA² and the presence of a RAN polypeptide.^{5,6} We considered that it is crucial to unravel the role of each element in the molecular pathology of FXTAS to understand the progression of the disorder and its role in pathophysiology. Indeed, it is interesting to remind that neuronal abnormal dendritic morphology (e.g., reduced length and number of dendrites that display longer spines) has been observed in FXTAS neurons at a time of development when nuclear inclusions are not detectable.^{3,4,8–11} These findings suggest that some developmental abnormalities may contribute to the late manifestation of neurodegenerative process and/or that the disease appears, with subtle phenotypes, earlier than predicted up to date. So far, no specific treatment is available for FXTAS patients. A therapy based on allopregnanolone was shown to improve cognitive functioning in patients with FXTAS and to partially alleviate some aspects of neurodegeneration,²¹ opening the possibility to search for new targetable pathways in young patients. In this study, we used a murine model of FXTAS to investigate the impact that the reduced level of *Fmr1* mRNA, but not of its encoded protein, has on the morphological and molecular phenotypes of FXTAS cultured neurons. Certainly, by reducing *Fmr1* mRNA levels, we are also supposed to reduce RAN levels, which is possibly involved in the pathophysiology of FXTAS.⁶ However, that peptide was never detected at endogenous levels in neurons so far.^{3,22}

First, we defined phenotypes that were never considered before in cultured cortical neurons obtained from the FXTAS mouse




Figure 3. Reduction of *Fmr1* mRNA Levels Normalizes Dendritic Spine Morphology in KI Cortical Neurons

(A) Representative high-resolution confocal images showing dendritic spine morphology were assessed using NeuronStudio software and compared with the measurement obtained from control transduced neurons. Scale bars: 2 μm . All histograms present mean \pm SEM values. Statistical significance was assessed by one-way ANOVA with Tukey's multiple comparisons test. (B–G) Histograms showing the mean \pm SEM values of (B) protrusion frequency in the various cultures, * $p < 0.05$; (C) spine length, *** $p < 0.001$; (D) spine head size, *** $p < 0.001$; (E) percentage of thin spines; (F) percentage of stubby spines; and (G) percentage of mushroom spines.

model: axon length and dendrite morphology. All of these new phenotypes are detected in cells not yet displaying nuclear inclusions, which are known to first appear in hippocampal neurons of 12-week-old KI-CGG mice.⁹ Interestingly, these animals have mild learning and memory deficits,^{4,9} and this behavioral phenotype is consistent with the phenotype that we observed in cultured cortical neurons. Importantly, we confirm that these phenotypes are associated with the levels of *Fmr1* mRNA because they are rescued after the expression of shRNAs specifically targeting this mRNA. We can deduce that an elevated abundance of *Fmr1* mRNA may interfere with normal RNA metabolism. We can predict that the overexpression of *Fmr1* mRNA may also likely interfere with the normal activity of RNA binding proteins or microRNAs (miRNAs) in neuronal soma, and at the synapse by competing for their binding at specific sites or at miRNA response elements (MREs).¹³ All of these considerations suggest that *Fmr1* mRNA metabolism can be regulated by a large number of RNA binding proteins and can be co-regulated with a plethora of other RNAs. For this reason, as the second step of our study, we performed a differential proteomic analysis of neurons expressing control or *Fmr1*-specific shRNAs, and we observed that a set of proteins, whose expression is deregulated in KI-CGG neurons, is normalized after treatment. Consistently, several proteins rescued by *Fmr1*-specific shRNAs are RNA binding proteins (e.g., Tial1,

Hnrnp11, and ROAA). In addition, some proteins whose levels were rescued by the reduction of *Fmr1* mRNA abundance are involved in the regulation of actin cytoskeleton dynamics, which is known to modulate the morphology of neurons and, in particular, of dendritic spines. Defective synaptic actin regulation seems to be involved in different neurodevelopmental and psychiatric disorders.²³ Interestingly, we have shown here that in KI-CGG neurons, dendritic spines are more numerous, and they appear overall longer and with a larger head, but the percentage of the various types of spines is unchanged. These results are consistent with a previous study displaying longer, but not immature, spines in the CGG-KI visual cortex.¹⁶ In addition, our findings suggest that, at least at 20 DIV, the elevated levels of *Fmr1* mRNA do not interfere with the spine maturation process but cause subtle abnormalities of their features, which may have an impact on synaptic transmission. Other rescued proteins belong to the Rab-GTPase family, a sub-class of the RAS superfamily, which spatially and temporally orchestrates specific vesicular trafficking that is critical for synaptic function in neurons in brain developmental disorders,²⁴ as well as in Parkinson's disease.²⁵ Along the same direction, another interesting protein is CLIP2, a cytoplasmic linker factor that is considered as a mediator between organelles and the cytoskeleton.²⁶ Consistent with their role in neurons, mutants of this class of proteins are associated with impaired cognitive

Table 1. Proteins Differentially Expressed in the Different Samples Studied

Name	UniProt Accession Number	WT-C	KI-C	WT-C/ Ki-C	Log (Fold Change)	p Value	KI-1a	WT-C/ Ki-1a	Log (Fold Change)	p Value	KI-1b	WT-C/ KI-1b	Log (Fold Change)	p Value
sp O89023 TPP1_MOUSE	O89023	0.00	0.93	0.00	NA	0.00001	0.00	NA	NA	1.00000	0.00	NA	NA	1.00000
sp P05132 KAPCA_MOUSE	P05132	5.16	10.17	0.51	-0.29	0.00132	5.83	0.89	-0.05	0.81905	4.79	1.08	0.03	0.81905
sp P21126 UBL4A_MOUSE	P21126	0.33	1.53	0.21	-0.67	0.04762	0.66	0.49	-0.31	0.51266	0.38	0.85	-0.07	0.51266
sp P21278 GNA11_MOUSE	P21278	7.43	4.06	1.83	0.26	0.03470	6.49	1.14	0.06	0.69780	7.98	0.93	-0.03	0.69780
sp P24369 PPIB_MOUSE	P24369	8.43	12.31	0.68	-0.16	0.03540	6.73	1.25	0.10	0.68137	9.91	0.85	-0.07	0.68137
sp P30677 GNA14_MOUSE	P30677	2.57	0.93	2.77	0.44	0.04928	2.40	1.07	0.03	0.88974	3.24	0.79	-0.10	0.88974
sp P35283 RAB12_MOUSE	P35283	5.82	3.08	1.89	0.28	0.00979	5.87	0.99	0.00	0.95886	5.51	1.06	0.02	0.95886
sp P52912 TIA1_MOUSE	P52912	0.00	0.93	0.00	NA	0.00001	0.00	NA	NA	1.00000	0.32	0.00	NA	1.00000
sp P56371 RAB4A_MOUSE	P56371	5.81	3.08	1.89	0.28	0.00560	5.87	0.99	0.00	0.94159	5.19	1.12	0.05	0.94159
sp Q80TS3 AGRL3_MOUSE	Q80TS3	0.97	2.16	0.45	-0.35	0.01678	0.37	2.64	0.42	0.17665	0.38	2.53	0.40	0.17665
sp Q8BGH2 SAM50_MOUSE	Q8BGH2	2.28	0.29	7.74	0.89	0.01329	2.07	1.10	0.04	0.79778	2.13	1.07	0.03	0.79778
sp Q8BHC4 DCAKD_MOUSE	Q8BHC4	0.00	0.93	0.00	NA	0.00001	0.31	0.00	NA	0.37390	0.00	NA	NA	0.37390
sp Q8CHT0 AL4A1_MOUSE	Q8CHT0	2.94	0.63	4.64	0.67	0.02926	2.43	1.21	0.08	0.54007	1.95	1.51	0.18	0.54007
sp Q91ZR1 RAB4B_MOUSE	Q91ZR1	5.82	3.68	1.58	0.20	0.02923	5.51	1.05	0.02	0.71442	5.19	1.12	0.05	0.71442
sp Q921F4 HNRL1_MOUSE	Q921F4	0.97	0.00	∞	NA	0.00000	0.98	0.99	0.00	0.98875	0.78	1.24	0.09	0.98875
sp Q922D8 C1TC_MOUSE	Q922D8	1.28	2.78	0.46	-0.34	0.00809	0.92	1.40	0.15	0.72353	1.29	1.00	0.00	0.72353
sp Q99020 ROAA_MOUSE	Q99020	1.63	0.31	5.34	0.73	0.04589	1.69	0.97	-0.02	0.90543	2.19	0.74	-0.13	0.90543
sp Q99PU5 ACBG1_MOUSE	Q99PU5	2.92	1.55	1.88	0.27	0.01399	2.73	1.07	0.03	0.62466	2.61	1.12	0.05	0.62466
sp Q9CPY7 AMPL_MOUSE	Q9CPY7	1.61	3.38	0.48	-0.32	0.00921	2.00	0.81	-0.09	0.53465	1.43	1.13	0.05	0.53465
sp Q9CW03 SMC3_MOUSE	Q9CW03	0.33	1.53	0.21	-0.67	0.04762	0.71	0.46	-0.34	0.64890	0.38	0.85	-0.07	0.64890
sp Q9CYR6 AGM1_MOUSE	Q9CYR6	0.33	1.86	0.18	-0.75	0.01091	0.00	∞	∞	0.37390	0.32	1.04	0.02	0.37390
sp Q9DCN2 NB5R3_MOUSE	Q9DCN2	4.53	6.79	0.67	-0.18	0.00385	4.79	0.95	-0.02	0.62926	4.48	1.01	0.00	0.62926
sp Q9WTX2 PRKRA_MOUSE	Q9WTX2	0.33	1.53	0.21	-0.67	0.04762	0.00	∞	∞	0.37390	0.00	∞	∞	0.37390
sp Q9Z0H8 CLIP2_MOUSE	Q9Z0H8	4.51	8.09	0.56	-0.25	0.04003	4.68	0.96	-0.02	0.88427	5.62	0.80	-0.10	0.88427
tr A0A087WPM2 A0A087WPM2_MOUSE	A0A087WPM2	1.94	2.78	0.70	-0.16	0.00099	1.64	1.18	0.07	0.61624	1.12	1.73	0.24	0.61624
tr A0AUM9 A0AUM9_MOUSE	A0AUM9	0.00	0.93	0.00	NA	0.00001	0.00	NA	NA	1.00000	0.00	NA	NA	1.00000
tr D3YZ68 D3YZ68_MOUSE	D3YZ68	39.80	47.10	0.84	-0.07	0.03447	38.80	1.03	0.01	0.89853	36.50	1.09	0.04	0.89853
tr E9Q7C9 E9Q7C9_MOUSE	E9Q7C9	7.46	9.91	0.75	-0.12	0.03009	5.75	1.30	0.11	0.10120	7.97	0.94	-0.03	0.10120
tr S4R232 S4R232_MOUSE	S4R232	5.50	3.04	1.81	0.26	0.03279	5.50	1.00	0.00	0.99389	5.17	1.06	0.03	0.99389

NA, not applicable.




Figure 4. Gene Ontology Classification of Rescued Proteins in KI-CGG Neurons

(A and B) The DAVID Gene Ontology Functional Annotation Clustering tool⁴⁰ was used to show functional classification of rescued proteins in KI-CGG neurons involved in (A) nucleotide-GTP binding and (B) RNA binding.

functions.^{21,24,27} Importantly, we also found mitochondrial proteins (e.g., pyrroline-5-carboxylate dehydrogenase [Aldh4a1/P5CDH] and Samm50) that are deregulated in CGG-KI neurons, confirming the importance of mitochondria in the pathophysiology of FXTAS, as previously reported by independent studies.^{28,29} This result suggests that an altered mitochondrial function is probably involved in early phenotypes of this disorder. Remarkably, the levels of those proteins were normalized by the reduction of *Fmr1* mRNA abundance. Thus, our data show molecular alterations that may contribute to explain the neurodevelopmental phenotypes of the mouse model and patients carrying the CGG premutation, thus providing an indication for future early therapies to treat CGG-premutation carriers. For instance, Aldh4a1/P5CDH is a mitochondrial matrix NAD(+)-dependent dehydrogenase that catalyzes the second step of the proline degradation pathway, converting pyrroline-5-carboxylate to glutamate. Altered function of this enzyme can result in a deregulation of the glutamate signaling, which is at the basis of various forms of brain disorders, as well as of Parkinson’s disease.^{30,31} Thus, Aldh4a1/P5CDH could be a therapeutic target for FXTAS patients during different periods of life and phases of the disorder associated with the CGG premutation. Other targets may be small GTPases by

using, in this case, a strategy based on the modulation of their regulators, as recently proposed.^{32,33} In conclusion, by our approach, we defined altered pathways in FXTAS neurons that are due to the increased levels of *Fmr1* mRNA and impact on neuronal morphology. They represent the molecular pathology underpinning the late FXTAS phenotype. In particular, differentially expressed proteins between WT and CGG-KI neurons are promising pharmacological targetable molecules for early therapeutic intervention for FXTAS. On the other side, future gene therapies could also target the CGG-repeat by excising it, as already shown in an induced pluripotent stem cell (iPSC) line.³⁴

MATERIALS AND METHODS

Animals

The experiments were performed following the Animals in Research: Reporting *In Vivo* Experiments (ARRIVE) guidelines.³⁵ *Fmr1* knockin (KI) and wild-type (WT) mice on a C57BL/6J congenic background were produced as described previously.³⁶ All animals were generated and housed in groups of four in standard laboratory conditions (22°C, 55% ± 10% humidity, and 12-h light/12-h dark diurnal cycles) with food and water provided *ad libitum*. Animal care was

conducted in accordance with the European Community Directive 2010/63/EU. All experiments were approved by the local ethics committee (Comité d’Ethique en Expérimentation Animale CIEPAL-AZUR N. 00788.01).

Lentivirus Generation

Lentivirus particles were produced as previously described.³⁷

Axon Length Measurements

Dissociated neurons were transfected with lentivirus plasmids by using Nucleofector as previously described.¹³ Neurons were cultured for 48 h and then fixed. Axons were labeled with anti-Tuj1 antibody, and the size of individual growing axons (distance from the soma to the tip of the axon) was manually measured using the ImageJ software.¹⁵

Neuronal Culture and Dendritic Spine Morphology Analysis

Primary neurons were prepared from E15.5 pregnant C57BL/6 *Fmr1*^{CGG/y} and WT mice as previously described.^{12,15} Neurons (5 days *in vitro*) were transduced with lentivirus as previously described.¹² Transduced neurons (20 days *in vitro*) were rinsed twice in PBS at room temperature (RT) after 19 h of transduction and then fixed with 4% paraformaldehyde and Triton-permeabilized. Sequential confocal images (512 × 220 pixels; zoom 3.0; average 4; speed 7) of GFP-expressing neurons were acquired with a 63× oil-immersion lens (NA 1.4) on an inverted Zeiss LSM780 confocal microscope. z series of seven to eight images of randomly selected secondary dendrites were analyzed using the NeuronStudio software, which allows for the automated detection and quantification of dendrite parameters and morphological classification, as previously performed.¹⁵

Protein Extraction and Western Blot Analysis

Immunoblotting was performed as follows: cells or grinded tissues were homogenized in lysis buffer, and debris was removed by centrifugation (20,000 × g, 10 min, 4°C).³⁸ Protein content in the supernatant was measured using the Bradford assay (Bio-Rad), and samples were separated on NuPAGE Bis-Tris 4%–12% gels in MOPS buffer. Separated proteins were transferred to nitrocellulose membranes (Bio-Rad). Membranes were blocked with PBS-Tween (0.05%) and milk (5%), and incubated with primary antibodies overnight.

Antibodies

The monoclonal 1C3 anti-FMRP antibody³⁹ was used at a 1:1,000 dilution, the anti-Tuj1 (BioLegend; TUJ1 1-15-56) antibody was used following the manufacturer’s instructions, and the monoclonal anti-β-tubulin antibody (Sigma) was used at a 1:10,000 dilution.

qRT-PCR

qPCR was performed on a LightCycler 480 (Roche) with MasterMix SYBRGreen (Roche) as previously described.¹³ Primers used to amplify *Fmr1* mRNA were previously reported.³⁷

Protein Identification and Analysis

Proteomic analysis was performed as previously described¹⁷ and resulted in the identification of around 2,000 proteins for each condition. These proteins were then compared to highlight the proteins identified under only one condition or under several conditions (“on/off” effect) and to highlight proteins predominantly identified in one condition relative to another (up if ratio >2, down if ratio <0.5). In order to compile a short list of differentially regulated proteins, a Student’s t test was performed after normalization of the spectral count quantification data. This allowed us to obtain a p value used to make this short list: from the global alignment table of the 2,888 different proteins, we focused on proteins with a p value threshold less than 0.10.

Statistical Analysis

Results are expressed as mean ± SEM. All statistical analyses were based on biological replicates. Appropriate statistical tests used for each experiment are described in the corresponding figure legends. All statistical analyses were carried out using GraphPad Prism version 6.0e.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.omtn.2019.09.018>.

AUTHOR CONTRIBUTIONS

M.D., S.D., T.M., S.M., M.G., F.B., M.J., and M.C. performed the experiments; R.W. and R.K.H. provided material; T.M., E.L., and B.B. designed the experiments; M.C., E.L., R.K.H., and B.B. wrote the manuscript.

CONFLICTS OF INTEREST

The authors declare no competing interests.

ACKNOWLEDGMENTS

The authors are grateful to S. Zongaro, P. Hammann, L. Khunn, and S. Abekhouk for help. This study was supported by CNRS, INSERM, Association Française contre les Myopathies (AFM), Fondation Recherche Médicale (FRM) grant DEQ20140329490, Fondation Recherche sur le Cerveau (FRC), and Agence Nationale de la Recherche grants ANR-15-CE16-0015 and ANR-11-LABX-0028-01. M.D. and S.C. were recipients of a fellowship from the international PhD LabEx “Signalife” Program. S.D. was a recipient of a MRES fellowship.

REFERENCES

- Bardoni, B., Mandel, J.L., and Fisch, G.S. (2000). *FMR1* gene and fragile X syndrome. *Am. J. Med. Genet.* 97, 153–163.
- Tassone, F., Hagerman, R.J., Taylor, A.K., Gane, L.W., Godfrey, T.E., and Hagerman, P.J. (2000). Elevated levels of *FMR1* mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. *Am. J. Hum. Genet.* 66, 6–15.
- Hagerman, P. (2013). Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. *Acta Neuropathol.* 126, 1–19.
- Berman, R.F., Buijssen, R.A., Usdin, K., Pintado, E., Kooy, F., Pretto, D., Pessah, I.N., Nelson, D.L., Zalewski, Z., Charlet-Berguerand, N., et al. (2014). Mouse models of the

- fragile X premutation and fragile X-associated tremor/ataxia syndrome. *J. Neurodev. Disord.* 6, 25.
5. Kearse, M.G., Green, K.M., Krans, A., Rodriguez, C.M., Linsalata, A.E., Goldstrohm, A.C., and Todd, P.K. (2016). CGG Repeat-Associated Non-AUG Translation utilizes a cap-dependent scanning mechanism of initiation to produce toxic proteins. *Mol. Cell* 62, 314–322.
 6. Sellier, C., Buijsen, R.A.M., He, F., Natla, S., Jung, L., Tropel, P., Gaucherot, A., Jacobs, H., Meziane, H., Vincent, A., et al. (2017). Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome. *Neuron* 93, 331–347.
 7. Hessel, D., and Grigsby, J. (2016). Fragile X-associated tremor/ataxia syndrome: another phenotype of the fragile X gene. *Clin. Neuropsychol.* 30, 810–814.
 8. Hunsaker, M.R., Arque, G., Berman, R.F., Willemsen, R., and Hukema, R.K. (2012). Mouse models of the fragile X premutation and the fragile X associated tremor/ataxia syndrome. *Results Probl. Cell Differ.* 54, 255–269.
 9. Hunsaker, M.R., Wenzel, H.J., Willemsen, R., and Berman, R.F. (2009). Progressive spatial processing deficits in a mouse model of the fragile X premutation. *Behav. Neurosci.* 123, 1315–1324.
 10. Chen, Y., Tassone, F., Berman, R.F., Hagerman, P.J., Hagerman, R.J., Willemsen, R., and Pessah, I.N. (2010). Murine hippocampal neurons expressing *Fmr1* gene premutations show early developmental deficits and late degeneration. *Hum. Mol. Genet.* 19, 196–208.
 11. Cunningham, C.L., Martínez Cerdeño, V., Navarro Porras, E., Prakash, A.N., Angelastro, J.M., Willemsen, R., Hagerman, P.J., Pessah, I.N., Berman, R.F., and Noctor, S.C. (2011). Premutation CGG-repeat expansion of the *Fmr1* gene impairs mouse neocortical development. *Hum. Mol. Genet.* 20, 64–79.
 12. Abekhoukh, S., Sahin, H.B., Grossi, M., Zongaro, S., Maurin, T., Madrigal, I., Kazue-Sugioka, D., Raas-Rothschild, A., Doulazmi, M., Carrera, P., et al. (2017). New insights into the regulatory function of CYFIP1 in the context of WAVE- and FMRP-containing complexes. *Dis. Model. Mech.* 10, 463–474.
 13. Zongaro, S., Hukema, R., D'Antoni, S., Davidovic, L., Barbry, P., Catania, M.V., Willemsen, R., Mari, B., and Bardoni, B. (2013). The 3' UTR of *FMR1* mRNA is a target of miR-101, miR-129-5p and miR-221: implications for the molecular pathology of FXTAS at the synapse. *Hum. Mol. Genet.* 22, 1971–1982.
 14. Nimchinsky, E.A., Oberlander, A.M., and Svoboda, K. (2001). Abnormal development of dendritic spines in *FMR1* knock-out mice. *J. Neurosci.* 21, 5139–5146.
 15. Maurin, T., Melancia, F., Jarjat, M., Castro, L., Costa, L., Delhaye, S., Khayachi, A., Castagnola, S., Mota, E., Di Giorgio, A., et al. (2018). Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome. *Cereb. Cortex* 29, 3241–3252.
 16. Berman, R.F., Murray, K.D., Arque, G., Hunsaker, M.R., and Wenzel, H.J. (2012). Abnormal dendrite and spine morphology in primary visual cortex in the CGG knock-in mouse model of the fragile X premutation. *Epilepsia* 53 (Suppl 1), 150–160.
 17. Rottloff, S., Miguel, S., Biteau, F., Nisse, E., Hammann, P., Kuhn, L., Chicher, J., Bazile, V., Gaume, L., Mignard, B., et al. (2016). Proteome analysis of digestive fluids in *Nepenthes* pitchers. *Ann. Bot.* 117, 479–495.
 18. Chonchaiya, W., Schneider, A., and Hagerman, R.J. (2009). Fragile X: a family of disorders. *Adv. Pediatr.* 56, 165–186.
 19. Schluter, E.W., Hunsaker, M.R., Greco, C.M., Willemsen, R., and Berman, R.F. (2012). Distribution and frequency of intranuclear inclusions in female CGG KI mice modeling the fragile X premutation. *Brain Res.* 1472, 124–137.
 20. Entezam, A., Biacci, R., Orrison, B., Saha, T., Hoffman, G.E., Grabczyk, E., Nussbaum, R.L., and Usdin, K. (2007). Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model. *Gene* 395, 125–134.
 21. Wang, J.Y., Trivedi, A.M., Carrillo, N.R., Yang, J., Schneider, A., Giulivi, C., Adams, P., Tassone, F., Kim, K., Rivera, S.M., et al. (2017). Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome. *Neurotherapeutics* 14, 1073–1083.
 22. Ma, L., Herren, A.W., Espinal, G., Randol, J., McLaughlin, B., Martínez-Cerdeño, V., Pessah, I.N., Hagerman, R.J., and Hagerman, P.J. (2019). Composition of the Intranuclear Inclusions of Fragile X-associated Tremor/Ataxia Syndrome. *Acta Neuropathol Commun* 7, 143.
 23. Yan, Z., Kim, E., Datta, D., Lewis, D.A., and Soderling, S.H. (2016). Synaptic Actin Dysregulation, a Convergent Mechanism of Mental Disorders? *J. Neurosci.* 36, 11411–11417.
 24. Mignogna, M.L., and D'Adamo, P. (2018). Critical importance of RAB proteins for synaptic function. *Small GTPases* 9, 145–157.
 25. Gao, Y., Wilson, G.R., Stephenson, S.E.M., Bozdoglu, K., Farrer, M.J., and Lockhart, P.J. (2018). The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease. *Mov. Disord.* 33, 196–207.
 26. Vandeweyer, G., Van der Aa, N., Reyniers, E., and Kooy, R.F. (2012). The contribution of CLIP2 haploinsufficiency to the clinical manifestations of the Williams-Beuren syndrome. *Am. J. Hum. Genet.* 90, 1071–1078.
 27. Ramakers, G.J. (2002). Rho proteins, mental retardation and the cellular basis of cognition. *Trends Neurosci.* 25, 191–199.
 28. Hukema, R.K., Buijsen, R.A., Raske, C., Severijnen, L.A., Nieuwenhuizen-Bakker, I., Minneboon, M., Maas, A., de Crom, R., Kros, J.M., Hagerman, P.J., et al. (2014). Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo. *Cell Cycle* 13, 2600–2608.
 29. Alvarez-Mora, M.L., Rodriguez-Revenga, L., Madrigal, I., Guitart-Mampel, M., Garrabou, G., and Milà, M. (2017). Impaired Mitochondrial Function and Dynamics in the Pathogenesis of FXTAS. *Mol. Neurobiol.* 54, 6896–6902.
 30. Naaijen, J., Lythgoe, D.J., Zwiers, M.P., Hartman, C.A., Hoekstra, P.J., Buitelaar, J.K., and Aarts, E. (2018). Anterior cingulate cortex glutamate and its association with striatal functioning during cognitive control. *Eur. Neuropsychopharmacol.* 28, 381–391.
 31. Carrillo-Mora, P., Sila-Adaya, D., and Villaseñor-Aguayo, K. (2013). Glutamate in Parkinson's disease: Role of anticholinergic drugs. *Basal Ganglia* 3, 147–157.
 32. O'Gorman Tuura, R.L., Baumann, C.R., and Baumann-Vogel, H. (2018). Beyond Dopamine: GABA, Glutamate, and the Axial Symptoms of Parkinson Disease. *Front. Neurol.* 9, 806.
 33. Gray, J.L., von Delft, F., and Brennan, P. (2019). Targeting the Small GTPase Superfamily through their Regulatory Proteins. *Angew. Chem. Int. Ed. Engl.* Published online March 14, 2019. <https://doi.org/10.1002/anie.201900585>.
 34. Xie, N., Gong, H., Suhl, J.A., Chopra, P., Wang, T., and Warren, S.T. (2016). Reactivation of *FMR1* by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome. *PLoS ONE* 11, e0165499.
 35. Kilkenny, C., Browne, W.J., Cuthill, I.C., Emerson, M., and Altman, D.G. (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLoS Biol.* 8, e1000412.
 36. Bontekoe, C.J., Bakker, C.E., Nieuwenhuizen, I.M., van der Linde, H., Lans, H., de Lange, D., Hirst, M.C., and Oostra, B.A. (2001). Instability of a (CGG)₉₈ repeat in the *Fmr1* promoter. *Hum. Mol. Genet.* 10, 1693–1699.
 37. Khalfallah, O., Jarjat, M., Davidovic, L., Nottet, N., Cestèle, S., Mantegazza, M., and Bardoni, B. (2017). Depletion of the Fragile X mental retardation protein in embryonic stem cells alters the kinetics of neurogenesis. *Stem Cells* 35, 374–385.
 38. Maurin, T., Lebrigand, K., Castagnola, S., Paquet, A., Jarjat, M., Popa, A., Grossi, M., Rage, F., and Bardoni, B. (2018). HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein. *Nucleic Acids Res.* 46, 6344–6355.
 39. Bardoni, B., Castets, M., Huot, M.E., Schenck, A., Adinolfi, S., Corbin, F., Pastore, A., Khandjian, E.W., and Mandel, J.-L. (2003). 82-FIP, a novel FMRP (fragile X mental retardation protein) interacting protein, shows a cell cycle-dependent intracellular localization. *Hum. Mol. Genet.* 12, 1689–1698.
 40. Huang, D.W., Sherman, B.T., Tan, Q., Collins, J.R., Alvord, W.G., Roayaei, J., Stephens, R., Baseler, M.W., Lane, H.C., and Lempicki, R.A. (2007). The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. *Genome Biol.* 8, R183.